Drug intelligence / Profile preview

diltiazem

Development stage
Approved
Lead developer
Mitsubishi Tanabe Pharma
Modality
Small Molecules
Administration
Oral, Intravenous, Rectal
01

Overview

Diltiazem is a non-dihydropyridine calcium channel blocker used to treat hypertension (high blood pressure), angina pectoris (chronic stable chest pain), and certain cardiac arrhythmias such as atrial fibrillation and atrial flutter. It works primarily by inhibiting the influx of calcium ions into cardiac and vascular smooth muscle cells during depolarization. This action relaxes blood vessels and reduces the workload on the heart by lowering blood pressure and increasing oxygen supply to the myocardium. Compared to other calcium channel blockers like nifedipine or verapamil that have more selective effects on either vascular or cardiac tissue respectively, diltiazem displays intermediate specificity for both tissues. It is available in oral formulations for chronic use and as an intravenous injection for acute arrhythmias[2][3][5][7].

Brand names
CardizemCardizem CDCardizem LACartia XTDilacor XRDilt-CDDiltia XTDilt-XRDiltzacMatzim LATaztia XTTiazacAcalixAdizemAltiazemAnohealCalcicardCartia (international)Dilacor (international)Dilcontin (international)Dilrene (international)Dilticard (international)Dilzem (international)Herbesser
Other names
benzothiazepine derivative
02

Targets

CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)

Beyond the preview

Go deeper on diltiazem.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on diltiazem.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call